Press "Enter" to skip to content

Patent delisted for Boehringer Ingelheim drug TRIJARDY XR

1
Copyright © DrugPatentWatch. Originally published at Patent delisted for Boehringer Ingelheim drug TRIJARDY XR

Annual Drug Patent Expirations for TRIJARDY+XR
Trijardy Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are fifteen patents protecting this drug.

Drug patent litigation for TRIJARDY XR.

This drug has four hundred and fifty-one patent family members in forty-seven countries.

The generic ingredient in TRIJARDY XR is empagliflozin; linagliptin; metformin hydrochloride. One supplier is listed for this compound. Additional details are available on the empagliflozin; linagliptin; metformin hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at Patent delisted for Boehringer Ingelheim drug TRIJARDY XR
    Get the DrugPatentWatch Daily Briefing

    ✓ Patent Expirations and Generic Entry

    ✓ Insightful Articles & Case Studies

    ✓ Patent Litigation & Challenges

    ✓ 505(b)(2) & Biosimilars

    ✓ Industry Trends

    Do NOT follow this link or you will be banned from the site!